Scholarlink

<p>Pancreatic cancer (PDAC) surveillance programs are recommended for individuals with a PDAC lifetime-risk ≥ 5% to improve outcomes. While familial adenomatous polyposis (FAP) is linked to increased PDAC risk, robust data to guide surveillance recommendations is lacking. This study evaluates PDAC risk in a large FAP-cohort.Data were collected from FAP cohorts in the United States (US) and the Netherlands (NL), including individuals (≥ 18 years) with a confirmed (likely) pathogenic APC variant. Cumulative PDAC incidence, adjusted for death as competing risk, was compared with control data from the Netherlands Cancer Registry and Statistics Netherlands. Data were collected from FAP cohorts in the United States (US) and the Netherlands (NL), including individuals (≥ 18 years) with a confirmed (likely) pathogenic <i>APC</i> variant. Cumulative PDAC incidence, adjusted for death as competing risk, was compared with control data from the Netherlands Cancer Registry and Statistics Netherlands. The US-cohort (<i>n</i> = 357) and NL-cohort (<i>n</i> = 1000) had a median age at the end of follow-up of 46 years (IQR, 32.0–60.0) and 60 years (IQR, 47.5–72.5), respectively. The cumulative risk of PDAC by age 70 was 1.3% (95% CI, 0.2–8.4) in the US cohort and 0.6% (95% CI 0.2–1.7) in the NL cohort. When combining both FAP-cohorts, the cumulative risk of PDAC by age 70 was 0.7% (95% CI, 0.3–1.8). For comparison, the cumulative incidence of PDAC in the general population at age 70 was 0.3% (95% CI 0.3–0.3), corresponding to a relative risk of 2.2 (95% CI, 0.9–5.7). Our findings indicate that PDAC risk in FAP patients is not statistically significantly higher than in the general population. As the cumulative incidence remains below the 5% threshold, PDAC surveillance is not recommended.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pancreatic cancer surveillance not recommended for familial adenomatous polyposis: a fine and gray risk analysis

  • 期刊论文

  • 发表日期：

    2025年11月25日

查看全文
  • Aleksander M. Bogdanski,
  • Derk C.F. Klatte,
  • Sobia I. Laghari,
  • Alexandra M.J. Langers,
  • Ananya Das,
  • Barbara A.J. Bastiaansen,
  • Bert A. Bonsing,
  • Evelien Dekker,
  • Jeanin E. Van Hooft,
  • Jewel N. Samadder,
  • Lodewijk A.A. Brosens,
  • Lydia G. van der Geest,
  • Lisa Boardman,
  • Maartje Nielsen,
  • Mariëtte C.A. van Kouwen,
  • Tanya M. Bisseling,
  • Michael B. Wallace,
  • Douglas Riegert-Johnson,
  • Monique E. van Leerdam

摘要

Pancreatic cancer (PDAC) surveillance programs are recommended for individuals with a PDAC lifetime-risk ≥ 5% to improve outcomes. While familial adenomatous polyposis (FAP) is linked to increased PDAC risk, robust data to guide surveillance recommendations is lacking. This study evaluates PDAC risk in a large FAP-cohort.Data were collected from FAP cohorts in the United States (US) and the Netherlands (NL), including individuals (≥ 18 years) with a confirmed (likely) pathogenic APC variant. Cumulative PDAC incidence, adjusted for death as competing risk, was compared with control data from the Netherlands Cancer Registry and Statistics Netherlands. Data were collected from FAP cohorts in the United States (US) and the Netherlands (NL), including individuals (≥ 18 years) with a confirmed (likely) pathogenic APC variant. Cumulative PDAC incidence, adjusted for death as competing risk, was compared with control data from the Netherlands Cancer Registry and Statistics Netherlands. The US-cohort (n = 357) and NL-cohort (n = 1000) had a median age at the end of follow-up of 46 years (IQR, 32.0–60.0) and 60 years (IQR, 47.5–72.5), respectively. The cumulative risk of PDAC by age 70 was 1.3% (95% CI, 0.2–8.4) in the US cohort and 0.6% (95% CI 0.2–1.7) in the NL cohort. When combining both FAP-cohorts, the cumulative risk of PDAC by age 70 was 0.7% (95% CI, 0.3–1.8). For comparison, the cumulative incidence of PDAC in the general population at age 70 was 0.3% (95% CI 0.3–0.3), corresponding to a relative risk of 2.2 (95% CI, 0.9–5.7). Our findings indicate that PDAC risk in FAP patients is not statistically significantly higher than in the general population. As the cumulative incidence remains below the 5% threshold, PDAC surveillance is not recommended.